| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Inhibits Mast Cell Fc
RI Expression 1
* Molecular Inflammation Section, Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892;
Biology Department, University of Richmond, Richmond, VA 23173; and Departments of
Internal Medicine and
Biology, Virginia Commonwealth University, Richmond, VA 23284
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
RI) is a critical component of atopic inflammation. The cytokine TGF-
1 has been shown to inhibit IgE-dependent mast cell activation, possibly serving to dampen mast cell-mediated inflammatory responses. We present proof that TGF-1 inhibits mast cell FcRI expression through a reversible pathway that diminishes protein, but not mRNA, expression of the FcRI subunit proteins 
, , and 
. The stability of the expressed proteins and the assembled cell surface complex was unaltered by TGF-1 treatment. However, TGF-1 decreased the rate of FcRI -chain synthesis, arguing that this inhibitory cytokine exerts its effects at the level of mRNA translation. TGF-1 consistently diminished FcRI expression on cultured human or mouse mast cells as well as freshly isolated peritoneal mast cells. The related cytokines, TGF-2 and TGF-3, had similar effects. We propose that TGF-1 acts as a negative regulator of mast cell function, in part by decreasing FcRI expression. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
superfamily is a large group of structurally related, highly conserved growth factors that includes TGF-1, TGF-2, TGF-3, activins, and bone morphogenetic proteins. TGF-1, the prototypic family member, is synthesized as a precursor polypeptide and secreted in a latent form by most tissues and cell types. The biologically active protein is a disulfide-linked homodimer (1). Signaling by TGF- family members occurs through interaction with serine/threonine kinase receptors termed type I and type II that, when activated, phosphorylate Smad proteins. Smads form complexes and translocate to the nucleus, where they regulate transcription of target genes together with other cofactors (reviewed in Refs.2 and 3). TGF- family members have stimulatory or inhibitory effects in regulating a wide variety of cellular functions, including apoptosis, differentiation, and proliferation. A vast number of studies have implicated TGF- proteins in several different physiological processes, including inflammation, fibrosis, and angiogenesis. Importantly, TGF- proteins have been linked to autoimmune disease, atherosclerosis, fibrotic disease, and cancer in humans (4, 5). A number of studies showing the inhibitory effects of TGF-1 on immune cell function (reviewed in Ref.5) support the role of TGF-1 as a suppressor of immunity and inflammation. Underscoring the importance of TGF-mediated immunosuppression is the observation that TGF-1-null mice develop severe inflammation, wasting syndrome, and organ failure, leading to death by 3 wk of age (6, 7).
Mast cell activation by cross-linking of the heterotetrameric high affinity receptor for IgE (FcRI) results in the release of preformed vasoactive amines and de novo synthesized cytokines, chemokines, and PGs (8). FcRI is composed of a ligand-binding -chain, a signal-augmenting -chain, and a signal-transducing -chain dimer. The FcRI and subunits contain ITAMs that, upon receptor aggregation, bind Src homology domain 2-containing signaling molecules to promote a signaling cascade causing mediator release (8). Mast cells are responsible for immediate hypersensitivity responses. Their widespread distribution in the skin and respiratory tract suggests a role as for these cells as a first-line defense against invading pathogens. However, unregulated activation can result in deleterious effects. In fact, mast cells are often associated with human allergic disease and are implicated in mouse models of the autoimmune diseases multiple sclerosis and, recently, rheumatoid arthritis (9, 10).
Given the role of mast cells in allergic and inflammatory disease and the inhibitory effect of TGF- on immune cells, the possibility exists that TGF- is a paracrine or autocrine inhibitor of mast cell function. It has been shown in separate studies that TGF-1 inhibited IL-3-dependent proliferation of mouse peritoneal mast cells and bone marrow-derived mast cells (BMMCs)
3 (11, 12). In addition, TGF-1 inhibited the rescue of BMMCs from IL-3 deprivation-induced apoptosis by stem cell factor (SCF) (13). Inhibitory effects of TGF-1 on mast cell effector functions have also been documented. Bissonette et al. (14) showed that Ag-induced histamine and TNF- production from rat peritoneal mast cells were inhibited by TGF-1, whereas Meade et al. (15) showed that in vivo treatment with TGF-1 inhibited an IgE-mediated, mast cell-dependent, immediate hypersensitivity response in mice. Despite these studies supporting the idea that TGF-1 inhibits mast cell function, contradicting evidence exists about the ability of TGF-1 to directly inhibit mast cell degranulation. This includes a report by Kim and Lee (16) that TGF-1 potentiates the IgE-dependent anaphylaxis reaction. Moreover, these studies have not revealed the mechanism of action by which TGF- acts on mast cells. This study was undertaken to assess a direct effect of TGF-1 on mast cell IgE receptor expression as a means of dampening mast cell effector responses.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
DNP-conjugated human serum albumin and cycloheximide were purchased from Sigma-Aldrich. Murine IL-3, SCF, and TGF-1 were purchased from R&D Systems. 2.4G2 (rat anti-mouse FcRII/RIII), mouse IgE, and FITC-conjugated rat anti-mouse kit were purchased from BD Pharmingen. FITC-conjugated rat anti-mouse IgE was purchased from Southern Biotechnology Associates. The anti-human FcRI- mAb, 3B4, was a gift from G. Mackay (University of Melbourne, Melbourne, Australia). Nonspecific human IgG (clone MOPC) was obtained from Sigma-Aldrich.
Mast cell cultures
BMMC were derived from C57BL/6 or BL6 x 129 mice by culture of bone marrow cells in complete RPMI 1640 medium (cRPMI), supplemented with 25% WEHI-3 cell-conditioned medium or with IL-3 and SCF (30 ng/ml each). After 3–4 wk in culture, >95% of these cells were mast cells, as judged by morphology and surface expression of FcRI and Kit (data not shown). These cells were used within 3 mo of their maturation. Peritoneal cells were harvested from euthanized animals by lavage of the peritoneum using 5 ml of cRPMI injected into the peritoneal cavity. These cells were cultured in cRPMI/IL-3 and SCF. Human umbilical cord blood-derived mast cell populations were derived as described previously (17).
Tissue culture conditions and flow cytometry to measure inhibition of FcRI expression
Cells were washed and replated at 3 x 105 cells/ml, 200 µl/well, in 96-well, flat-bottom plates. IL-3 was added to 5 ng/ml, followed by the indicated concentrations of TGF-1 or mouse IgE. The use of SCF (30 ng/ml) in some experiments did not alter the results. Cultures were incubated for the indicated times. Every 4 days half the media and cytokines or IgE were replaced. Mast cell surface Ag expression was assessed by flow cytometry as described previously (18). The mean fluorescence intensity of IgE staining was used to determine the percent inhibition of FcRI expression caused by the addition of TGF-1.
Mast cell activation assays
To assess -hexosaminidase release or cytokine secretion, BMMC were cultured in IL-3 with or without TGF-1 as described above, then activated with mouse IgE (10 µg/ml, 45 min, 4°C) and the indicated concentrations of DNP-BSA for 1 h (-hexosaminidase release) or 9 h (cytokine secretion). After activation, -hexosaminidase release was measured as previously described (19). The percent -hexosaminidase release was determined by dividing the amount of -hexosaminidase in the supernatant by the total amount detected in the supernatant and cell pellet. TNF- or IL-6 secretion was measured by standard ELISA (R&D Systems).
RNase protection assay (RPA)
RPA assays were performed using the RiboQuant system (BD Pharmingen) according to the manufacturer’s instructions. Pixel intensities of individual bands were obtained using a Typhoon PhosphorImager (Molecular Dynamics). The ratio of the pixel intensity for each band of interest to the sum of the pixel intensities for the housekeeping genes (L32 and GAPDH) in that lane were determined. Calculations of percent change in expression relative to control conditions were determined by comparing these ratios.
35S labeling and Western blot analysis
FcRI, -, and - subunits as well as actin were detected by immunoprecipitation and Western blotting as described previously (20). For immunoprecipitation of FcRI, lysates from 30 x 106 cells were incubated with 50 µl of protein A-Sepharose conjugated to 25 µg of rabbit anti-mouse IgG (Jackson ImmunoResearch Laboratories) and 5 µg of anti-FcRI (clone 5.14; gift from Z. Eshhar, Weizmann Institute, Rehovat, Israel). Immunoprecipitates were analyzed by Western blotting with 1 µg/ml anti-FcRI (clone TW; gift from B. Baird and D. Holowka, Cornell University, Ithaca, NY). Although both the 5.14 and TW Ab clones are specific for rat FcRI -chain, they cross-react with mouse -chain. Anti--chain immunoprecipitates were subjected to electrophoresis without reducing agents to prevent cross-reactivity of the detection Ab with the precipitating H chain. FcRI and FcRI were detected by Western blotting of total cell lysates using 1.2 µg/ml anti-FcRI (clone JRK) or a 1/10,000 dilution of anti--chain (clone 06-727; Upstate Cell Signaling Solutions). For 35S labeling, BMMC were incubated in cysteine- and methionine-free RPMI 1640 with 5% FCS for 2.5 h, then pulsed for 20 min with 800 mCi/ml 35S-labeled cysteine and methionine. Lysates were sequentially immunoprecipitated with anti-FcRI and anti-actin. Immunoprecipitates were resolved by gel electrophoresis and subjected to phosphorimaging. The ratio of -chain to actin bands was used to compare samples treated or not treated with TGF-1.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
inhibits FcRI expression on mast cells
TGF-1 has been shown to inhibit FcRI-dependent mast cell degranulation and TNF- production (14), an effect confirmed in our experiments. Mouse BMMC cultured for 3 days with or without TGF-1 were stimulated by IgE and Ag. TGF-1 reduced -hexosaminidase release 50–60% over a range of Ag concentrations and decreased the IgE-mediated production of both TNF- and IL-6 (Fig. 1). This potent inhibition of IgE-mediated signaling led us to question the effects of TGF-1 on FcRI expression.
|
1 on mast cell FcRI surface expression. BMMC were cultured in IL-3 with or without TGF-1 for 3 days, after which receptor expression was analyzed. Flow cytometric analysis revealed that FcRI surface expression was markedly reduced on BMMC cultured with TGF-1 (Fig. 2A). These results were consistent using 15 different BMMC populations derived from individual mice. The kinetics of TGF-1 effects were measured in time-course and dose-response experiments. We found that TGF-1 decreased surface FcRI expression within the first 24 h of culture, and that maximal inhibition (60%) occurred on days 3–4 of culture (Fig. 2B). Importantly, the reduction in FcRI expression was not due to decreased cell viability. TGF-1 had no effect on cell death, as judged by propidium iodide or trypan blue staining (data not shown). The inhibitory effect of TGF-1 showed a concentration dependence, with 50% inhibition of FcRI expression occurring at 
2 ng/ml TGF-1 (Fig. 2C). Lastly, the related cytokines, TGF-2 and TGF-3, also decreased FcRI surface expression (Fig. 2D), indicating that this inhibitory effect was consistent among TGF family members.
|
1 on FcRI expression was restricted to BMMC, we tested other mast cell populations. Peritoneal cells from C57BL6 mice were cultured for 3 days in IL-3 with or without TGF-1. After loading FcRI with IgE, peritoneal exudate cells were double-stained for Kit and IgE, then analyzed by flow cytometry. As shown in Fig. 3A, IgE receptor staining intensity on peritoneal mast cells (IgE+Kit+) cultured in IL-3 and TGF-1 was reduced >70% compared with that on cells cultured in IL-3 alone. These results indicated that the effects of TGF-1 also were apparent on mature mast cells developed in vivo. Human mast cells also decreased FcRI expression in response to TGF-1. As shown in Fig. 3B, human mast cells that were derived from cord blood, then cultured for 3 days in SCF and TGF-1 exhibited a nearly complete loss of FcRI expression compared with cells maintained in SCF alone. These data indicate that TGF-1-mediated inhibition was not a consequence of in vitro development conditions and is consistent in human and mouse models.
|
1 on occupied IgE receptors
It has been reported that monomeric IgE increases mast cell FcRI expression (21, 22, 23), an effect that could be critical to IgE-elicited inflammatory responses in atopic disease. To determine whether TGF-1 could alter the effects of monomeric IgE, we cultured BMMC with or without IgE for 4 days to up-regulate FcRI expression, then added TGF-1 for an additional 3 days. As shown in Fig. 4, TGF-1 reduced FcRI expression on cells that had previously been cultured with IgE. However, the effects of TGF-1 appeared to be less potent when IgE was present, because the decrease in FcRI surface expression averaged 31% compared with 50–60% without IgE (Fig. 2). These data indicate that TGF-1-mediated down-regulation of FcRI can occur on occupied receptors, but to a lesser extent than on unoccupied receptors.
|
on FcRI subunit mRNA and protein expression
To determine the mechanism by which TGF-1 negatively regulates expression of the IgE receptor, we assessed mRNA and protein levels of the FcRI, -, and - subunits in BMMCs cultured with IL-3 and SCF with or without TGF-1. No significant differences in mRNA expression were detected by RPA after culture with or without TGF-1 for 6, 24, or 72 h (Fig. 5). In contrast, TGF-1 substantially decreased total , , and protein expression, as shown by Western blotting (Fig. 6). Densitometric analysis showed that the FcRI subunit was decreased 34% (n = 2), whereas the and subunits were each inhibited nearly 70% (, 67.7 ± 11.8% (n = 4); , 70.6 ± 14.2% (n = 3)). Collectively, these data indicate that changes in FcRI transcription or mRNA stability are not the mechanisms by which TGF-1 decreases IgE receptor expression. Instead, this inhibition appears to be accomplished through a post-transcriptional mechanism that leads to reduced expression of all three FcRI subunits, particularly the - and -chains.
|
|
1-mediated FcRI inhibition. In washout experiments, we found that the effects of TGF-1 were reversible over a 24- to 48-h period. BMMC were cultured for 3 days in the presence of TGF-1, then washed extensively and replated in IL-3 and SCF with no added TGF-1. As shown in Fig. 7A, the effect of TGF-1 was diminished within 24 h, and normal IgE receptor expression was restored within 48 h of TGF-1 removal. Thus, TGF-1-mediated inhibition of FcRI expression was maintained only when this cytokine was present.
|
1 occurred post-transcriptionally, it was possible that diminished FcRI expression was mediated by degradation of the receptor subunits. To address this issue, we treated BMMCs that had been cultured for 3 days in the presence or the absence of TGF-1 with the protein synthesis inhibitor cycloheximide and assessed surface FcRI expression by flow cytometry as well as total FcRI subunit expression by Western blotting. The day 3 time point was chosen because it demonstrated maximal effects of TGF-1 that were maintained through at least day 7 (Fig. 2B). As shown in Fig. 7, B and C, cycloheximide treatment decreased the expression of surface FcRI and total FcRI subunit at rates that were not affected by the presence of TGF-1. These data indicated that TGF-1 inhibits FcRI expression by a reversible post-transcriptional mechanism that does not involve enhanced receptor endocytosis or protein degradation.
One explanation for reduced FcRI expression in the absence of altered endocytosis or degradation could be that TGF-1 reduces the rate of FcRI protein synthesis. We determined the effect of TGF-1 on the rate of FcRI -chain synthesis. BMMC cultured for 3 days in IL-3 and TGF-1 before incubation with 35S-labeled methionine and cysteine showed a significant reduction in FcRI -chain synthesis compared with cells cultured in IL-3 alone (Fig. 7D). Using actin production as a reference, TGF-1-treated cells showed a 60–75% reduction in FcRI -chain protein production. These data argue that TGF-1 controls expression of the mast cell IgE receptor by inhibiting FcRI protein synthesis, leading to reduced surface expression and function.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Mast cells are responsive to many cytokines that can provide homeostatic control. We have recently found that IL-4 and IL-10 exert such effects partly through control of FcRI expression. To gain a complete view of how cytokines control mast cell activity, we have sought other factors capable of similar regulatory function. Recently, Tridandapani et al. (24) demonstrated that TGF-1 could inhibit FcR -chain expression on myeloid cells and monocytes. Because this subunit is shared among several FcRs, including FcRI, it appeared possible that TGF-1 might regulate mast cell FcRI expression. Furthermore, TGF-1 diminishes IgE-mediated histamine release and TNF- production in vitro (14) and inhibits in vivo mast cell responses (15). TGF-1 has also been shown to inhibit IL-3-, IL-4-, and SCF-mediated signaling in mast cells, decreasing survival and proliferation (11, 12, 13). In contrast, TGF-1 has been reported to elicit mast cell migration (25, 26). Hence, like IL-4 and IL-10, TGF-1 appears to have both positive and negative effects on mast cell function. These effects might be mediated by mast cells in an autocrine fashion, because mast cells produce IL-4, IL-10, and TGF-1. Furthermore, mast cell proteases are reportedly capable of cleaving latent TGF-1 (27, 28). It is also interesting to note that polymorphisms in the TGF-1 promoter region have been shown to segregate with asthmatic families that have elevated serum IgE (29). These data encouraged our interest in TGF-1 as a mediator of mast cell homeostasis.
We show in the current work that TGF-1 inhibits mast cell FcRI surface expression, with peak effects after 3 days of culture. This inhibition was consistently found in cultured mouse mast cells, freshly isolated peritoneal mouse mast cells, and cultured human mast cells, making it unlikely that our data are related to culture artifacts or species differences. The effects of TGF-1 were reproduced using the related cytokines TGF-2 and TGF-3, which, like TGF-1, signal through TGF- receptors I and II (1). This inhibitory signaling was sensitive, occurring at a concentration of 1 ng/ml. Mast cells express >100,000 FcRI molecules/cell, a fraction of which need to be aggregated to elicit signaling (8). Therefore, it is interesting to note that TGF-1 reduced surface FcRI expression 60%, leaving many more receptors than needed for activation. Consistent with other studies, we found that the reduction in FcRI expression correlated with significantly reduced IgE-mediated activation. Specifically, TGF-1 inhibited IgE-mediated mast cell degranulation and TNF- production, as shown by Bissonette et al. (14). We also found that production of the inflammatory cytokine IL-6 was decreased. Furthermore, the ability of monomeric IgE to increase FcRI expression was dampened by TGF-1, an effect that could be critical in patients with chronically elevated serum IgE. Thus, the effects of TGF-1 were consistent among distinct mast cell populations and were functionally relevant.
The timing of TGF-1-mediated inhibitory effects was reminiscent of our previous work with IL-4 and IL-10, both of which diminished FcRI expression after 3 days of culture (18, 20). We have postulated that this delay in inhibitory signaling may frame an inflammatory window during which mast cell responses elicit inflammation to control infection. IL-4, IL-10, and TGF-1 would be produced during the T cell- and mast cell-mediated responses that characterize inflammation elicited by IgE. It is intriguing that these cytokines may initially offer survival or migration signals to mast cells, but subsequently inhibit mast cell function and survival. Both the timing and the effects of this cytokine-mediated response fit a description of homeostasis.
The similarities among IL-4, IL-10, and TGF-1 were partly conserved in their mechanism of action. Like IL-4 and IL-10, TGF-1 inhibited FcRI expression without significantly altering the expression of the mRNAs encoding the three FcRI subunits. Instead, the protein expression of all three subunits was decreased after TGF-1 treatment and occurred without any notable change in protein stability. Like the study by Tridandapani et al. (24), we noted a decrease in FcR -chain expression. We also noted a similar decrease in FcRI -chain expression. This is an interesting point of regulation, because IL-4 and IL-10 also reduced FcRI expression. As shown by several studies, FcRI is a central regulator of FcRI expression and function, serving as an amplifier of the IgE response (30, 31, 32, 33). -Chain targeting by these cytokines emphasizes the importance of this subunit as a point of control in IgE receptor function.
The inhibition of FcRI expression by TGF-1 may be mediated at the level of protein synthesis. Thus, TGF-1-stimulated BMMC synthesized FcRI at a rate at least 60% slower than that in control cells. Our data provide a model in which TGF-1 reduces IgE receptor expression by controlling the rate of translation without altering mRNA expression or the stability of the proteins produced. This model is supported by a recent paper demonstrating the phosphorylation of eukaryotic initiation factor 2 by TGF-1 receptor (34), which could decrease the synthesis of some proteins. Post-transcriptional control is typically used for flexible, rapid changes in expression, consistent with the reversibility of the TGF-1 effects we observed. In fact, the effects of TGF-1 were fairly transient, with a loss of inhibition 36–48 h after TGF-1 was removed from the culture medium. Hence, the reversible nature of the effects of TGF-1 fits our theory of how this cytokine alters IgE receptor expression.
These data support the theory that TGF-1 produced by mast cells or other cells involved in the inflammatory cascade provides a delayed and reversible inhibition of IgE-mediated mast cell inflammatory function. The delay in its effects is postulated to allow protective mast cell responses, which are dampened after 3 days to avert chronic inflammation. These effects are exerted at the level of protein production, creating a nimble homeostatic system to control the potent effector functions of mast cells.
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Footnotes |
|---|
1 This work was supported in part by grants to the Ryan laboratory from the National Institutes of Health (1RO1AI43433 and 1R01CA91839). 
2 Address correspondence and reprint requests to Dr. John J. Ryan, Biology Department, Virginia Commonwealth University, Box 842012, Richmond, VA 23284-2012. E-mail address: jjryan{at}saturn.vcu.edu
3 Abbreviations used in this paper: BMMC, bone marrow-derived mast cell; cRPMI, complete RPMI 1640 medium; RPA, RNase protection assay; SCF, stem cell factor.
Received for publication September 14, 2004. Accepted for publication March 1, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
family. Annu. Rev. Cell Biol. 6: 597-641.[Medline]
signaling from cell membrane to the nucleus. Cell 113: 685-700.[Medline]
SMAD signaling. Trends Biochem. Sci. 29: 265-273.[Medline]
in human disease. N. Engl. J. Med. 342: 1350-1358.. Annu. Rev. Immunol. 16: 137-161.[Medline]
1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90: 770-774.1 gene results in multifocal inflammatory disease. Nature 359: 693-699.[Medline]
RI signaling and the allergic response. Curr. Opin. Immunol. 14: 688-693.[Medline]
1 inhibits IL-3- and IL-4-dependent mouse connective tissue-type mast cell proliferation. Arch. Dermatol. Res. 287: 198-201.[Medline]
1 selectively inhibits IL-3-dependent mast cell proliferation without affecting mast cell function or differentiation. J. Immunol. 143: 1591-1597.[Abstract]
prevents stem cell factor-mediated rescue of mast cells from apoptosis after IL-3 deprivation. J. Immunol. 153: 2194-2203.[Abstract]
1 inhibits the release of histamine and tumor necrosis factor- from mast cells through an autocrine pathway. Am. J. Respir. Cell Mol. Biol. 16: 275-282.[Abstract]
1 inhibits murine immediate and delayed type hypersensitivity. J. Immnuol. 149: 521-528.[Abstract]
1 on the IgE-dependent anaphylaxis reaction. J. Immnuol. 162: 4960-4965.RII with FcRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J. Biol. Chem. 279: 35139-35149.RI expression through a STAT6-dependent mechanism. J. Immunol. 161: 6915.-hexosminidase and -glucuronidase from purified rat serosal mast cells. J. Immunol. 123: 1445-1450.RI expression in mouse mast cells. J. Immunol. 172: 3181-318.RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J. Exp. Med. 185: 663.1 suppresses myeloid Fc receptor function by regulating the expression and function of the common -subunit. J. Immunol. 170: 4572-457.-mediated mast cell migration depends on mitogen-activated protein kinase activity. Cell Signal 13: 483-490.[Medline]
family. J. Leukocyte Biol. 67: 350-356.[Abstract]
1 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem. 270: 4689-4696.1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J. 15: 1377-1388. promoter polymorphisms in allergies and asthma. Am. J. Respir. Crit. Care Med. 158: 1958-1962.chain deletion results in pleiotrophic effector cell defects. Cell 76: 519.[Medline]
RI subunit functions as an amplifier of FcRI mediated cell activation signals. Cell 85: 22076.
is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 8: 517-529.[Medline]
RI- subunit. Immunity 12: 515.[Medline]
subunit associates with TGF receptors and 14-3-3 and acts as a modulator of the TGF response. Biochemistry 41: 579-587.[Medline]This article has been cited by other articles:
|
|
 |
|
  X. Chen, B.-S. Feng, P.-Y. Zheng, X.-Q. Liao, J. Chong, S.-G. Tang, and P.-C. Yang Fc Gamma Receptor Signaling in Mast Cells Links Microbial Stimulation to Mucosal Immune Inflammation in the Intestine Am. J. Pathol., December 1, 2008; 173(6): 1647 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhao, G. Gomez, S.-H. Yu, J. J. Ryan, and L. B. Schwartz TGF-{beta}1 Attenuates Mediator Release and De Novo Kit Expression by Human Skin Mast Cells through a Smad-Dependent Pathway J. Immunol., November 15, 2008; 181(10): 7263 - 7272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kennedy Norton, B. Barnstein, J. Brenzovich, D. P. Bailey, M. Kashyap, K. Speiran, J. Ford, D. Conrad, S. Watowich, M. R. Moralle, et al. IL-10 Suppresses Mast Cell IgE Receptor Expression and Signaling In Vitro and In Vivo J. Immunol., March 1, 2008; 180(5): 2848 - 2854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kashyap, A. M. Thornton, S. K. Norton, B. Barnstein, M. Macey, J. Brenzovich, E. Shevach, W. J. Leonard, and J. J. Ryan Cutting Edge: CD4 T Cell-Mast Cell Interactions Alter IgE Receptor Expression and Signaling J. Immunol., February 15, 2008; 180(4): 2039 - 2043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Grayson, D. Cheung, M. M. Rohlfing, R. Kitchens, D. E. Spiegel, J. Tucker, J. T. Battaile, Y. Alevy, L. Yan, E. Agapov, et al. Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia J. Exp. Med., October 29, 2007; 204(11): 2759 - 2769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kurashima, J. Kunisawa, M. Higuchi, M. Gohda, I. Ishikawa, N. Takayama, M. Shimizu, and H. Kiyono Sphingosine 1-Phosphate-Mediated Trafficking of Pathogenic Th2 and Mast Cells for the Control of Food Allergy J. Immunol., August 1, 2007; 179(3): 1577 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Leeansyah, B. D. Wines, S. M. Crowe, and A. Jaworowski The Mechanism Underlying Defective Fc{gamma} Receptor-Mediated Phagocytosis by HIV-1-Infected Human Monocyte-Derived Macrophages J. Immunol., January 15, 2007; 178(2): 1096 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. O. Barnstein, G. Li, Z. Wang, S. Kennedy, C. Chalfant, H. Nakajima, K. D. Bunting, and J. J. Ryan Stat5 Expression Is Required for IgE-Mediated Mast Cell Function. J. Immunol., September 1, 2006; 177(5): 3421 - 3426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Cauvi, X. Tian, K. von Loehneysen, and M. W. Robertson Transport of the IgE Receptor {alpha}-Chain Is Controlled by a Multicomponent Intracellular Retention Signal J. Biol. Chem., April 14, 2006; 281(15): 10448 - 10460. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
